Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

872220

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Warrington Clinical Commissioning Group
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if his Department will take steps to ensure that the Chief Officer of Warrington Care Commissioning Group spending 50 per cent of his time as acting head of Halton clinical commissioning group does not detrimentally affect his management of Warrington Care Commissioning Group.
tabling member constituency	Warrington North
tabling member printed	Helen Jones
uin	134134
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>Dr Andrew Davies has the support of very experienced senior management teams, for both NHS Halton Clinical Commissioning Group (CCG) and NHS Warrington CCG. Dr Davies will undertake his role and accountabilities, attending committees and governing bodies for both CCGs. The joint senior management team meets weekly (every Monday) with Dr Davies attending and chairing each weekly meeting for assurance that all requirements are met and duties are discharged. Dr Davies’ diary commitments are managed effectively to ensure that his time is split equally between both CCGs as required.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 10:38:33 answering member 4067 label Biography information for Steve Brine
tabling member	432 label Biography information for Helen Jones

872221

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Warrington Clinical Commissioning Group
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 March 2018 to Question 131390, who the person was who made the decision to appoint the Chief Officer of Warrington clinical commissioning group as the acting, interim, Chief Officer of Halton clinical commissioning group.
tabling member constituency	Warrington North
tabling member printed	Helen Jones
uin	134135
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>NHS England has advised that the appointment of the Chief Officer is made by the leadership team of the Clinical Commissioning Group. Accountable Officer status is then confirmed by Simon Stevens, Chief Executive (and Accounting Officer) of NHS England.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:58:38 answering member 4067 label Biography information for Steve Brine
tabling member	432 label Biography information for Helen Jones

872243

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Incentives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of doctors who have been awarded bonuses by clinical commissioning groups limiting the number of patients they refer to hospital; and if he will make a statement.
tabling member constituency	Colne Valley
tabling member printed	Thelma Walker
uin	134157
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>NHS England confirms that no bonuses have been paid.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:59:45 answering member 4067 label Biography information for Steve Brine
tabling member	4649 label Biography information for Thelma Walker

872244

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Incentives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of doctors who have been awarded bonuses by clinical commissioning groups for limiting the number of patients they refer for cancer screening; and if he will make a statement.
tabling member constituency	Colne Valley
tabling member printed	Thelma Walker
uin	134158
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>NHS England does not hold this information.</p><p> </p><p>NHS England does not support bonus payments to general practitioners for reducing referrals.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:52:44 answering member 4067 label Biography information for Steve Brine
tabling member	4649 label Biography information for Thelma Walker

872270

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Out of Area Treatment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many (a) adults and (b) children and young people within the Sunderland Clinical Commissioning Group were sent out of area to receive mental health treatment in 2016-17.
tabling member constituency	Houghton and Sunderland South
tabling member printed	Bridget Phillipson
uin	134184
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The information requested is not collected for children and young people.</p><p> </p><p>For adults, data of out of area placements has been collected since October 2016, therefore information for 2016/17 is not available.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 29/03/2018 10:49:59 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4046 label Biography information for Bridget Phillipson

872272

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of treatments for patients diagnosed with Refractory B-cell Acute Lymphoblastic Leukaemia.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134186
answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134187 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872273

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with Refractory B-cell Acute Lymphoblastic Leukaemia have been unable to access treatments for that condition.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134187
answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134186 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872274

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer and Rare Diseases: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NICE appraisals for new treatments for rare (a) diseases and (b) cancers.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134188
answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>Most new drugs and significant licence indications are assessed by the National Institute for Health and Care Excellence (NICE) through its technology appraisal programme, through which NICE has been able to recommend a significant number of drugs for the treatment of rare cancers and other diseases for routine use on the National Health Service. NICE also operates a separate Highly Specialised Technology evaluation programme for the evaluation of a very small number of treatments for very rare diseases.</p><p>The methods and processes NICE uses in the development of its guidance are internationally respected, have been developed through extensive engagement with a full range of stakeholders, including the Department, and are regularly reviewed to ensure that they remain fit for purpose.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/04/2018 13:25:57 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872275

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) NHS England and (b) NICE on the development of (a) multi-indication pricing, (b) outcomes-based pricing and (c) annuity deals for new treatments.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134189
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The Department has regular and ongoing dialogue with NHS England and the National Institute for Health and Care Excellence on matters related to medicines pricing and patient access to new treatments. We will consider all relevant issues in upcoming discussions with the pharmaceutical industry on medicines pricing arrangements for 2019 onwards to succeed the current Pharmaceutical Price Regulation Scheme.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 14:02:10 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872282

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Facial Disfigurement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to ensure that people with facial disfigurements are not refused (a) medical and (b) surgical treatments for their condition on the grounds that such treatment is cosmetic.
tabling member constituency	Hampstead and Kilburn
tabling member printed	Tulip Siddiq
uin	134196
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>Reconstructive or plastic surgery can be available on the National Health Service. This is different from cosmetic surgery; it is surgery to restore a person's normal appearance after illness, accident or a birth defect. It includes procedures such as rebuilding breasts after a mastectomy, or repairing a cleft lip.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 14:03:19 answering member 4067 label Biography information for Steve Brine
tabling member	4518 label Biography information for Tulip Siddiq